A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06522828

Enrollment

Registered

2024-07-26

Start date

2024-10-10

Completion date

2026-08-31

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

Brief summary

This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.

Interventions

DRUGSSGJ-707

SSGJ-707 is a bispecific antibody against human PD-1 and VEGF

DRUGcarboplatin

chemotherapy

DRUGpaclitaxel

chemotherapy

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Age:18-75 years old 2. Advanced endometrial cancer and platinum-resistant ovarian cancer 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Expected survival \>=12 weeks. 5. Signed informed consent form.

Exclusion criteria

1. Known uncontrolled or symptomatic central nervous system metastatic disease. 2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0). 3. Inadequate organ or bone marrow function. 4. Pregnant or breast-feeding woman. 5. Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Design outcomes

Primary

Measure	Time frame	Description
Safety and tolerability	12 months	Safety and tolerability assessed by incidence and severity of adverse events
ORR	12 months	Objective response rate

Secondary

Measure	Time frame	Description
PFS	24 months	The efficacy end point

Countries

China

Contacts

Primary ContactZHOU, PhD

qizhou9128@163.com13708384529

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026